154 related articles for article (PubMed ID: 22593241)
1. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study.
Melvin JC; Seth D; Holmberg L; Garmo H; Hammar N; Jungner I; Walldius G; Lambe M; Wigertz A; Van Hemelrijck M
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1381-4. PubMed ID: 22593241
[TBL] [Abstract][Full Text] [Related]
2. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.
Melvin JC; Garmo H; Holmberg L; Hammar N; Walldius G; Jungner I; Lambe M; Van Hemelrijck M
BMC Cancer; 2017 Apr; 17(1):246. PubMed ID: 28376727
[TBL] [Abstract][Full Text] [Related]
3. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study.
Van Hemelrijck M; Garmo H; Hammar N; Jungner I; Walldius G; Lambe M; Holmberg L
Int J Cancer; 2012 May; 130(9):2118-28. PubMed ID: 21630265
[TBL] [Abstract][Full Text] [Related]
4. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.
Bahl M; Ennis M; Tannock IF; Hux JE; Pritchard KI; Koo J; Goodwin PJ
Breast Cancer Res Treat; 2005 Nov; 94(2):135-44. PubMed ID: 16261412
[TBL] [Abstract][Full Text] [Related]
5. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.
Van Hemelrijck M; Walldius G; Jungner I; Hammar N; Garmo H; Binda E; Hayday A; Lambe M; Holmberg L
Cancer Causes Control; 2011 Jul; 22(7):1011-9. PubMed ID: 21562751
[TBL] [Abstract][Full Text] [Related]
6. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer.
Delimaris I; Faviou E; Antonakos G; Stathopoulou E; Zachari A; Dionyssiou-Asteriou A
Clin Biochem; 2007 Oct; 40(15):1129-34. PubMed ID: 17673194
[TBL] [Abstract][Full Text] [Related]
7. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer.
Lambe M; Wigertz A; Garmo H; Walldius G; Jungner I; Hammar N
Cancer Causes Control; 2011 Aug; 22(8):1163-71. PubMed ID: 21688131
[TBL] [Abstract][Full Text] [Related]
8. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk.
Furberg AS; Veierød MB; Wilsgaard T; Bernstein L; Thune I
J Natl Cancer Inst; 2004 Aug; 96(15):1152-60. PubMed ID: 15292387
[TBL] [Abstract][Full Text] [Related]
9. Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project.
Bjørge T; Lukanova A; Tretli S; Manjer J; Ulmer H; Stocks T; Selmer R; Nagel G; Almquist M; Concin H; Hallmans G; Jonsson H; Häggström C; Stattin P; Engeland A
Int J Epidemiol; 2011 Dec; 40(6):1667-77. PubMed ID: 21984693
[TBL] [Abstract][Full Text] [Related]
10. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
[TBL] [Abstract][Full Text] [Related]
11. Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24,329 Norwegian women.
Vatten LJ; Foss OP
Cancer Res; 1990 Apr; 50(8):2341-6. PubMed ID: 2317820
[TBL] [Abstract][Full Text] [Related]
12. Serum lipids, lipid-lowering drugs, and the risk of breast cancer.
Eliassen AH; Colditz GA; Rosner B; Willett WC; Hankinson SE
Arch Intern Med; 2005 Oct; 165(19):2264-71. PubMed ID: 16246993
[TBL] [Abstract][Full Text] [Related]
13. Significance of alterations in plasma lipid profile levels in breast cancer.
Franky Dhaval Shah ; Shilin Nandubhai Shukla ; Pankaj Manubhai Shah ; Patel HR; Prabhudas Shankerbhai Patel
Integr Cancer Ther; 2008 Mar; 7(1):33-41. PubMed ID: 18292593
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer.
Hogervorst JG; Schouten LJ; Konings EJ; Goldbohm RA; van den Brandt PA
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2304-13. PubMed ID: 18006919
[TBL] [Abstract][Full Text] [Related]
15. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of women with metachronous breast and ovarian carcinomas.
Liou WS; Hamilton CA; Cheung MK; Osann K; Longacre TA; Teng NN; Husain A; Dirbas FM; Chan JK
Gynecol Oncol; 2006 Oct; 103(1):190-4. PubMed ID: 16569424
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer risk factors and second primary malignancies among women with breast cancer.
Trentham-Dietz A; Newcomb PA; Nichols HB; Hampton JM
Breast Cancer Res Treat; 2007 Oct; 105(2):195-207. PubMed ID: 17186360
[TBL] [Abstract][Full Text] [Related]
18. Risks of breast, endometrial, and ovarian cancers after twin births.
Ji J; Försti A; Sundquist J; Hemminki K
Endocr Relat Cancer; 2007 Sep; 14(3):703-11. PubMed ID: 17914100
[TBL] [Abstract][Full Text] [Related]
19. [Association of serum lipid profile with distant metastasis in breast cancer patients].
Liu YL; Qian HX; Qin L; Zhou XJ; Zhang B; Chen X
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):129-31. PubMed ID: 22780931
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project.
Bjørge T; Lukanova A; Jonsson H; Tretli S; Ulmer H; Manjer J; Stocks T; Selmer R; Nagel G; Almquist M; Concin H; Hallmans G; Häggström C; Stattin P; Engeland A
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1737-45. PubMed ID: 20615887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
